The battle against leprosy is far from over, but a powerful alliance is making strides towards a world free of this ancient disease. WHO's renewed pledge to eradicate leprosy shines a light on the critical role of partnerships, just in time for World Leprosy Day.
Leprosy, an age-old disease caused by the bacteria Mycobacterium leprae, primarily targets the skin and nerves. If untreated, it can lead to permanent disabilities, stigma, and social isolation. However, there's a beacon of hope: multidrug therapy (MDT) can cure it.
The global fight against leprosy has shown promising results, with 55 out of 188 reporting areas declaring zero new cases in 2024. But the battle isn't won yet; 172,717 new cases were still detected globally in the same year.
Enter Novartis, a pharmaceutical giant, which has been a steadfast ally in this fight since 2000. Together with WHO, they've provided MDT and clofazimine at no cost to leprosy patients worldwide. This enduring partnership is a shining example of how private-public collaboration can make a real difference.
But here's where it gets controversial... The partnership has been extended for another 5 years, ensuring continued access to MDT. But is this enough? The extension also includes funding for single-dose rifampicin (SDR) for post-exposure prophylaxis, which raises the question: should we be focusing on prevention as well as cure?
Dr. Jeremy Farrar, WHO's Assistant Director-General, praises the partnership's impact, stating that it has been instrumental in transforming lives and bringing us closer to a leprosy-free world. Dr. Lutz Hegemann from Novartis echoes this sentiment, emphasizing the company's historical commitment to fighting this disease.
The availability of free MDT has not only cured the disease but also prevented disabilities and reduced stigma, allowing patients to live normal lives. Clofazimine has played a crucial role in treating lepra reactions, which can cause severe disabilities if not addressed.
And this is the part most people miss: Sustaining this progress requires more than just medical solutions. It demands political commitment, community engagement, and continued collaboration. The theme for World Leprosy Day 2026 highlights this, focusing on the stigma surrounding the disease.
Mr. Yohei Sasakawa, WHO's Goodwill Ambassador for Leprosy Elimination, has witnessed the devastating impact of leprosy-related stigma during his 25 years of service. He emphasizes that the social consequences of leprosy often outlast the disease itself, leading to discrimination and social exclusion, even after successful treatment.
As leprosy is part of the Neglected Tropical Diseases (NTDs) group, efforts to combat it contribute to the broader goal of eliminating NTDs worldwide. This World NTD Day, join the global movement and learn how you can be part of this transformative journey.
